Research
Funding boost to support older adults with hearing loss

Academics from Swansea University in Wales have received £100,000 in funding to improve evidence and understanding around the importance of support for older adults with hearing loss.
The study, led by Dr Emma Richards and Professor Andrea Tales from the University’s Centre for Ageing and Dementia Research (CADR), is being supported through the UK Research and Innovation (UKRI) Healthy Ageing Challenge, which aims to help people remain active, productive, independent, and socially connected across generations for as long as possible.
Over five years, the challenge will invest up to £98 million in healthy ageing, enabling businesses, including social enterprises, to develop and deliver beneficial products, services, and business models.
As part of this, the team at Swansea will increase understanding of the difficulties people with hearing loss experience, such as hearing conversations in a variety of noisy and distracting places, such as shops, cafes, and public transport.
They will also look at how this noise affects not only hearing, but how it impacts attention, cognition, wellbeing, and social interaction.
This evidence will form the basis of addressing the problem, raising awareness of the issue amongst the public, retail and travel sectors, and the need to make hearing loss-related changes to environments.
Dr Emma Richards, Senior Research Officer at CADR, said: “Hearing loss is now recognised as the largest modifiable risk factor in the development of dementia, with a reported eight per cent of all dementia is caused by hearing loss.
“Hearing loss in older adulthood can lead to isolation and loneliness, and it can be especially difficult hearing conversations in noisy environments, leading to reluctance to go to such places and spaces.
“Arguably, hearing loss can be countered by hearing aids, with evidence indicating they can also reduce dementia risk, but, in reality, this often fails because they remain ineffective in many noisy environments.
“This reduces the ability of older adults with hearing loss to remain active, productive, independent, and socially connected, and this, together with hearing loss per se, represents a risk factor for the development of cognitive impairment and dementia.”
Professor Andrea Tales, Co-Director of CADR, added: “Discussions with audiologists and people attending their clinics reveal that noisy environments are problematic for people with hearing loss, even when a hearing aid is used.
“There is a lack of the research-based evidence specifically required to guide the changes needed for older adults with hearing loss, which this study, thanks to funding from UKRI, we hope will have a positive impact on.”
The team are currently looking for study participants, including:
- Individuals aged over 50 with hearing loss (communication partners are also welcome to attend).
- People who work in the retail, hospitality and transport sectors, with the ability to influence their work environment.
To find out more email Dr Emma Richards at E.V.Richards@swansea.ac.uk
News
Two teas or coffees a day could lower dementia risk, experts say
Insights
Genetic influence on lifespan underestimated by half
News
Aerska raises US$39m for brain RNA medicines

Biotechnology company Aerska has raised US$39m in Series A funding to develop brain-delivered RNA medicines.
The company is developing treatments for neurological diseases, including genetically driven forms of Alzheimer’s disease.
This takes Aerska’s total funding to US$60m, months after its seed funding announcement in October 2025.
The company’s platform uses what it calls “brain shuttle” technology to help RNA therapeutics cross the blood-brain barrier, a protective membrane that normally prevents many drugs reaching the brain. RNA interference is a biological process where RNA molecules can silence or reduce the activity of specific genes.
The approach is designed to allow intravenous or subcutaneous administration, with the aim of achieving uniform brain distribution.
The financing was led by EQT Dementia Fund and age1, with participation from Iaso Ventures, alongside existing investors.
Chief executive and co-founder Jack O’Meara said: “The ability to systemically administer RNAi therapies to the brain unlocks a powerful new approach to treating neurodegeneration.
“Partnering with EQT Dementia Fund further strengthens our path to the clinic as we work to translate this capability into meaningful therapies for the treatment of genetically-driven forms of Alzheimer’s disease and other devastating brain disorders.”
As part of the financing, Arno de Wilde, managing director at EQT, Philip Scheltens, partner and head of the Dementia Fund at EQT, and Alex Colville, general partner at age1, will join Aerska’s board of directors.
Scheltens said: “For families facing diseases like Alzheimer’s, Aerska’s approach offers hope for preserving cognitive function and quality of life.
“The team’s strategy of upstream intervention, combined with a focus on the genetic forms of neurological disease, positions them to transform outcomes for populations who have been underserved by current therapeutic approaches.
“We really look forward to working with this talented team to advance this groundbreaking platform.”
Research4 weeks agoInterview: GlycanAge launch first hospital-based tests
News3 weeks agoShingles vaccine may slow biological ageing in older adults
News4 weeks agoOlder male athletes may face increased risk of serious heart problems during exercise
News3 weeks agoThousands of men in England to be offered life-extending prostate cancer drug
News3 weeks agoNanoparticles target disease proteins in dementia
News3 weeks agoL-Nutra raises US$36.5m in series D funding
Research4 weeks agoBlood sugar spike after meals may increase Alzheimer’s risk
Insights4 weeks agoStudy reveals why memory declines with age






















